LCAOS
A Nanoscale Artificial Nose to easily detect Volatile Biomarkers at Early stages of Lung Cancer and Related Genetic Mutations
| Coordinatore | TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Organization address
address: TECHNION CITY - SENATE BUILDING contact info |
| Nazionalità Coordinatore | Israel [IL] |
| Totale costo | 5˙405˙173 € |
| EC contributo | 4˙140˙174 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-04-01 - 2015-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Organization address
address: TECHNION CITY - SENATE BUILDING contact info |
IL (HAIFA) | coordinator | 1˙211˙702.39 |
| 2 |
THE UNIVERSITY OF LIVERPOOL
Organization address
address: Brownlow Hill, Foundation Building 765 contact info |
UK (LIVERPOOL) | participant | 654˙457.80 |
| 3 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 577˙099.95 |
| 4 |
TEL AVIV UNIVERSITY
Organization address
address: RAMAT AVIV contact info |
IL (TEL AVIV) | participant | 473˙367.18 |
| 5 |
UNIVERSIDAD COMPLUTENSE DE MADRID
Organization address
address: AVENIDA DE SENECA 2 contact info |
ES (MADRID) | participant | 412˙607.20 |
| 6 |
IONICON ANALYTIK GMBH
Organization address
address: EDUARD BODEM GASSE 3 contact info |
AT (INNSBRUCK) | participant | 328˙320.00 |
| 7 |
JLM INNOVATION GMBH
Organization address
address: BEETHOVENWEG 41 contact info |
DE (TUEBINGEN) | participant | 301˙435.20 |
| 8 |
MICRONIT MICROFLUIDICS BV
Organization address
address: COLOSSEUM 15 contact info |
NL (ENSCHEDE) | participant | 181˙185.01 |
| 9 |
Ionimed Analytik GmbH
Organization address
address: Eduard-Bodem-Gasse 3 contact info |
AT (Innsbruck) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The LCAOS project will develop and test a new diagnostic tool, able to detect: (i) the presence of lung cancer (LC), and (ii) an increased risk of a patient developing LC in the future. Diagnostic tests currently available are unsuitable for widespread screening because they are costly, occasionally miss tumours, are not time-efficient, nor free of complications. LCAOS will overcome these problems by using an approach based on volatile biomarkers emitted from cell membranes. A multidisciplinary effort, incorporating nanotechnology, biomedical engineering, medical oncology, and computation strategies, will develop a highly-sensitive, inexpensive, and fast-response, non-invasive, artificial nose (known as, NaNose), building on the coordinator’s earlier success in this area. The NaNose will be able to detect pre-neoplastic volatile biomarkers that indicate an increased genetic risk of LC, and the presence of LC. It has already been established that these biomarkers can be detected either directly from the headspace of the cancer cells or via exhaled breath. LCAOS will: (i) develop arrays of chemically-sensitive field effect transistors (FETs) of non-oxidized, molecule-terminated silicon nanowires (Si NWs); (ii) test the ability of these devices to sense volatile LC biomarkers from in-vitro tissue, and exhaled human breath; (iii) study the signal transduction mechanism of the volatile biomarkers, using pattern recognition; (iv) improve systems to enable the NaNose to distinguish the targeted biomarkers from environmental clutter, using methylation, expression profiling, and genome-wide sequencing; and (v) perform clinical-related studies to assess LC conditions in actual patients & tissues, and in the presence of real-world confounding signals. Validation will be carried out by clinician partners and professional mathematicians and computer scientists. Resources will also be allocated to ensure the commercial potential of the sensor device layout.'
Introduzione (Teaser)
Lung cancer (LC) is a devastating disease whose outcomes are significantly improved with early detection. Scientists are developing an inexpensive artificial nose to analyse exhaled breath and sense increased risk.